Precision medicine is the new paradigm of modern cancer treatment and gives hope to an increasing number of cancer patients. Unfortunately, fibroblast growth factor receptor (FGFR) aberrant cancers seem to lag behind this development mainly because FGFR inhibitors often fail or only give transient effects in clinical trials. To answer these challenges, we investigate how FGFR signalling is rewired in cancer cells in order to improve and develop novel strategies to target the FGFRs. We use a combination of functional proteomics, cell biological approaches and appropriate cancer cell and mouse models to achieve this. These results are integrated with data from patient biobanks in order to establish the relevance of our findings.